- Generic Name:
- Drug Type:
- Isocitrate dehydrogenase-1 (IDH1) inhibitor
- How the Drug is Given:
Indications and Usage
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Side effects needing medical attention
The most common adverse reactions, including laboratory abnormalities, aspartate aminotransferase increased (high levels means injury to the liver), alanine aminotransferase increased (high levels means injury to the liver), potassium decreased, sodium decreased, alkaline phosphatase increased (may be sign of liver problem), nausea, creatinine increased (may be sign of poor kidney function), fatigue/malaise, arthralgia (joint stiffness), constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea (difficult breathing), pyrexia (fever), rash, lipase increased (may be a problem with pancreas), mucositis (mouth or gut is sore and inflamed), diarrhea and transaminitis.